Tenaya Therapeutics (TNYA) Cash from Investing Activities (2020 - 2026)

Tenaya Therapeutics' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$11000.0 for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 100.05% year-over-year to -$11000.0 in Q1 2026; TTM through Mar 2026 was $33.8 million, a 20.94% increase from a year earlier, with the FY2025 full-year figure at $56.1 million, up 4858.71% from the prior year.
• Cash from Investing Activities grew to -$11000.0 in Q1 2026 per TNYA's latest filing, from -$67000.0 in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $31.0 million in Q3 2022 and bottomed at -$30.1 million in Q3 2024.
• The 5-year median for Cash from Investing Activities is $14.1 million (2024), against an average of $11.2 million.
• Across the five-year window, Cash from Investing Activities surged 1033.56% in 2022 and slumped 349.73% in 2023, its largest moves.
• Year by year, Cash from Investing Activities stood at $6.0 million in 2022, then slumped by 349.73% to -$14.9 million in 2023, then surged by 194.53% to $14.1 million in 2024, then slumped by 100.48% to -$67000.0 in 2025, then soared by 83.58% to -$11000.0 in 2026.
• Per Business Quant, the three latest TNYA Cash from Investing Activities figures stand at -$11000.0 (Q1 2026), -$67000.0 (Q4 2025), and $8.9 million (Q3 2025).